EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation

June 10, 2015

Conference | American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.

In this video, Steven I. Sherman, MD, of the MD Anderson Cancer Center in Houston, Texas, discusses the final overall survival analysis of EXAM, a randomized, placebo-controlled phase III trial studying cabozantinib in patients with progressive, locally advanced, or metastatic medullary thyroid carcinoma.